The effect of switching patients with asthma maintained on up to 2000 microg/day chlorofluorocarbon-beclomethasone dipropionate ( CFC-BDP ) , 1600 microg/day budesonide , 1000 microg/day fluticasone , or 2000 microg/day flunisolide , to a reduced dose of hydrofluoroalkane-134a BDP ( HFA-BDP ) extrafine aerosol ( maximum 800 microg/day ) was investigated during an open-label multicentre study .
